Yusuf Erkul

Company: Kernal Biologics
Job title: CEO
Bio:
Seminar: Onco-Selective mRNA Therapeutics for Cancer Immunotherapy
- Cancer ribosomes present unique opportunity for novel, onco-selective mRNA designs
- Onco-selective mRNAs encoding immunogenic cell death proteins results in highly effective oncolytic activity in vitro
- Onco-selective KR-333 mRNA LNPs enable robust antiactivity in syngeneic tumor models
Day: Day One